These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

643 related items for PubMed ID: 15315859

  • 1. A comparative evaluation of nasal and parenteral vaccine adjuvants to elicit systemic and mucosal HIV-1 peptide-specific humoral immune responses in cynomolgus macaques.
    Egan MA, Chong SY, Hagen M, Megati S, Schadeck EB, Piacente P, Ma BJ, Montefiori DC, Haynes BF, Israel ZR, Eldridge JH, Staats HF.
    Vaccine; 2004 Sep 09; 22(27-28):3774-88. PubMed ID: 15315859
    [Abstract] [Full Text] [Related]

  • 2. Mucosal immunity to HIV-1: systemic and vaginal antibody responses after intranasal immunization with the HIV-1 C4/V3 peptide T1SP10 MN(A).
    Staats HF, Nichols WG, Palker TJ.
    J Immunol; 1996 Jul 01; 157(1):462-72. PubMed ID: 8683152
    [Abstract] [Full Text] [Related]

  • 3. Comparison of intranasal with targeted lymph node immunization using PR8-Flu ISCOM adjuvanted HIV antigens in macaques.
    Koopman G, Bogers WM, van Gils M, Koornstra W, Barnett S, Morein B, Lehner T, Heeney JL.
    J Med Virol; 2007 May 01; 79(5):474-82. PubMed ID: 17385685
    [Abstract] [Full Text] [Related]

  • 4. Increased immunogenicity of HIV envelope subunit complexed with alpha2-macroglobulin when combined with monophosphoryl lipid A and GM-CSF.
    Liao HX, Cianciolo GJ, Staats HF, Scearce RM, Lapple DM, Stauffer SH, Thomasch JR, Pizzo SV, Montefiori DC, Hagen M, Eldridge J, Haynes BF.
    Vaccine; 2002 May 22; 20(17-18):2396-403. PubMed ID: 12009296
    [Abstract] [Full Text] [Related]

  • 5. HIV-1 neutralizing antibodies in the genital and respiratory tracts of mice intranasally immunized with oligomeric gp160.
    VanCott TC, Kaminski RW, Mascola JR, Kalyanaraman VS, Wassef NM, Alving CR, Ulrich JT, Lowell GH, Birx DL.
    J Immunol; 1998 Feb 15; 160(4):2000-12. PubMed ID: 9469464
    [Abstract] [Full Text] [Related]

  • 6. A recombinant P4 protein of Haemophilus influenzae induces specific immune responses biologically active against nasopharyngeal colonization in mice after intranasal immunization.
    Hotomi M, Ikeda Y, Suzumoto M, Yamauchi K, Green BA, Zlotnick G, Billal DS, Shimada J, Fujihara K, Yamanaka N.
    Vaccine; 2005 Jan 26; 23(10):1294-300. PubMed ID: 15652672
    [Abstract] [Full Text] [Related]

  • 7. Reduction of nasal colonization of nontypeable Haemophilus influenzae following intranasal immunization with rLP4/rLP6/UspA2 proteins combined with aqueous formulation of RC529.
    Mason KW, Zhu D, Scheuer CA, McMichael JC, Zlotnick GW, Green BA.
    Vaccine; 2004 Sep 03; 22(25-26):3449-56. PubMed ID: 15308371
    [Abstract] [Full Text] [Related]

  • 8. Induction of HIV-specific antibody response and protection against vaginal SHIV transmission by intranasal immunization with inactivated SHIV-capturing nanospheres in macaques.
    Miyake A, Akagi T, Enose Y, Ueno M, Kawamura M, Horiuchi R, Hiraishi K, Adachi M, Serizawa T, Narayan O, Akashi M, Baba M, Hayami M.
    J Med Virol; 2004 Jul 03; 73(3):368-77. PubMed ID: 15170630
    [Abstract] [Full Text] [Related]

  • 9. A combination HIV vaccine based on Tat and Env proteins was immunogenic and protected macaques from mucosal SHIV challenge in a pilot study.
    Ferrantelli F, Maggiorella MT, Schiavoni I, Sernicola L, Olivieri E, Farcomeni S, Pavone-Cossut MR, Moretti S, Belli R, Collacchi B, Srivastava IK, Titti F, Cafaro A, Barnett SW, Ensoli B.
    Vaccine; 2011 Apr 05; 29(16):2918-32. PubMed ID: 21338681
    [Abstract] [Full Text] [Related]

  • 10. Mucosal immunization with purified flagellin from Salmonella induces systemic and mucosal immune responses in C3H/HeJ mice.
    Strindelius L, Filler M, Sjöholm I.
    Vaccine; 2004 Sep 09; 22(27-28):3797-808. PubMed ID: 15315861
    [Abstract] [Full Text] [Related]

  • 11. Comparative ability of plasmid IL-12 and IL-15 to enhance cellular and humoral immune responses elicited by a SIVgag plasmid DNA vaccine and alter disease progression following SHIV(89.6P) challenge in rhesus macaques.
    Chong SY, Egan MA, Kutzler MA, Megati S, Masood A, Roopchard V, Garcia-Hand D, Montefiori DC, Quiroz J, Rosati M, Schadeck EB, Boyer JD, Pavlakis GN, Weiner DB, Sidhu M, Eldridge JH, Israel ZR.
    Vaccine; 2007 Jun 21; 25(26):4967-82. PubMed ID: 17335943
    [Abstract] [Full Text] [Related]

  • 12. Protective immunity against influenza H5N1 virus challenge in mice by intranasal co-administration of baculovirus surface-displayed HA and recombinant CTB as an adjuvant.
    Prabakaran M, Velumani S, He F, Karuppannan AK, Geng GY, Yin LK, Kwang J.
    Virology; 2008 Oct 25; 380(2):412-20. PubMed ID: 18786689
    [Abstract] [Full Text] [Related]

  • 13. The CBD1 peptide corresponding to the caveolin-1 binding domain of HIV-1 glycoprotein gp41 elicits neutralizing antibodies in cynomolgus macaques when administered with the tetanus T helper epitope.
    Benferhat R, Martinon F, Krust B, Le Grand R, Hovanessian AG.
    Mol Immunol; 2009 Feb 25; 46(4):705-12. PubMed ID: 19010547
    [Abstract] [Full Text] [Related]

  • 14. Humoral immune responses by prime-boost heterologous route immunizations with CTB-MPR(649-684), a mucosal subunit HIV/AIDS vaccine candidate.
    Matoba N, Geyer BC, Kilbourne J, Alfsen A, Bomsel M, Mor TS.
    Vaccine; 2006 Jun 05; 24(23):5047-55. PubMed ID: 16621185
    [Abstract] [Full Text] [Related]

  • 15. Durable HIV-1 antibody and T-cell responses elicited by an adjuvanted multi-protein recombinant vaccine in uninfected human volunteers.
    Goepfert PA, Tomaras GD, Horton H, Montefiori D, Ferrari G, Deers M, Voss G, Koutsoukos M, Pedneault L, Vandepapeliere P, McElrath MJ, Spearman P, Fuchs JD, Koblin BA, Blattner WA, Frey S, Baden LR, Harro C, Evans T, NIAID HIV Vaccine Trials Network.
    Vaccine; 2007 Jan 05; 25(3):510-8. PubMed ID: 17049679
    [Abstract] [Full Text] [Related]

  • 16. Intranasal immunization of young mice with a multigene HIV-1 vaccine in combination with the N3 adjuvant induces mucosal and systemic immune responses.
    Bråve A, Hallengärd D, Schröder U, Blomberg P, Wahren B, Hinkula J.
    Vaccine; 2008 Sep 19; 26(40):5075-8. PubMed ID: 18450334
    [Abstract] [Full Text] [Related]

  • 17. Protection of macaques against vaginal SHIV challenge by systemic or mucosal and systemic vaccinations with HIV-envelope.
    Barnett SW, Srivastava IK, Kan E, Zhou F, Goodsell A, Cristillo AD, Ferrai MG, Weiss DE, Letvin NL, Montefiori D, Pal R, Vajdy M.
    AIDS; 2008 Jan 30; 22(3):339-48. PubMed ID: 18195560
    [Abstract] [Full Text] [Related]

  • 18. Mucosal and systemic immune responses by intranasal immunization using archaeal lipid-adjuvanted vaccines.
    Patel GB, Zhou H, Ponce A, Chen W.
    Vaccine; 2007 Dec 12; 25(51):8622-36. PubMed ID: 17959279
    [Abstract] [Full Text] [Related]

  • 19. Intranasal administration is an effective mucosal vaccine delivery route for self-adjuvanting lipid core peptides targeting the group A streptococcal M protein.
    Olive C, Sun HK, Ho MF, Dyer J, Horváth A, Toth I, Good MF.
    J Infect Dis; 2006 Aug 01; 194(3):316-24. PubMed ID: 16826479
    [Abstract] [Full Text] [Related]

  • 20. Immunization with HIV-1 SF162-derived Envelope gp140 proteins does not protect macaques from heterologous simian-human immunodeficiency virus SHIV89.6P infection.
    Xu R, Srivastava IK, Kuller L, Zarkikh I, Kraft Z, Fagrouch Z, Letvin NL, Heeney JL, Barnett SW, Stamatatos L.
    Virology; 2006 Jun 05; 349(2):276-89. PubMed ID: 16527321
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 33.